Blog | Forum

Articles

Bookmark This Page

Genetics

Stem Cell Research

DNA

Gene Therapy

Genetic Testing

Genetic Engineering

Genomes

Chromosomes

Cloning

Genetic Research

Genetic Modification

TILLING: practical single-nucleotide mutation discovery.
Publication Date: 2006 Feb PMID: 16441355Authors: Comai, L. - Henikoff, S.Journal: Plant JIn the post-genomic sequencing era, an expanding portfolio of genomic technologies has been applied to the study of gene function. Reverse genetics approaches that provide targeted inactivation of genes identified by sequence analysis include TILLING (for Targeting Local Lesions IN Genomes). TILLING searches the genomes of mutagenized organisms for mutations in a chosen gene, typically single base-pair substitutions. This review covers practical aspects of the technology, ranging from building the mutagenized population to mutation discovery, and discusses possible improvements to current protocols and the impact of new genomic methods for mutation discovery in relation to the future of the TILLING approach.


Xpention Genetics, Inc.: Xpention Genetics Signs Technology License Agreement With The University of Texas MD Anderson Cancer Center
CONIFER, CO (MARKET WIRE) Xpention Genetics, Inc. (OTC BB: XPNG) and The University of Texas MD Anderson Cancer Center sign a Patent and Technology License Agreement.


Targeting key enzyme with gene therapy reversed course of Alzheimer's in mouse models
In mice, that had been genetically engineered to develop Alzheimer's disease, scientists were able to reverse the rodents' memory loss by reducing the amount of an enzyme that is crucial for the development of Alzheimer's disease. "What we are showing is a proof of principle that stopping the synthesis of a protein that is necessary for the formation of the telltale plaques reverses the progression of the disease, and more importantly, the cognitive function of these mice, which had already been impaired, has now recovered," says Inder Verma, professor in the Laboratory for Genetics at the Salk Institute for Biological Studies... click link for more info.


Viral Genetics, Inc.: Viral Genetics Updates on South African Clinical Development Initiatives
AZUSA, CA (MARKET WIRE) Viral Genetics, Inc. (OTC BB: VRAL), a drug development company developing a biological therapy for the treatment of HIV infection, today announced that it has completed the follow-up stage of the Phase 3 study of VGV-1 in South Africa. This double-blind, placebo-controlled, randomized, multi-center study of 137 HIV positive patients treated with either VGV-1 or placebo began enrollment in August


Supreme Court Denies Petition To Reverse Order For Reverse Bifurcation
The U.S. Supreme Court has denied a writ of certiorari to opt-out plaintiffs ordered by the diet drug MDL judge to submit their cases to a reverse-bifurcated trial (Linda Smart, et al., Petitioners v. Wyeth, No. 04-1580 U.S. Sup., 2005 U.S. LEXIS 5602; See June 2005, Page 6) Full story on lexis.com